Open AccessTREATMENTS OF HEPATITIS C VIRUS LIVER CIRRHOSIS WITH PEGYLAT INTERFERON-RIBAVIRIN AND INTERFERON FREE – COMPARATIVE STUDY
Author(s) -
Simin Aysel Florescu,
Ştefan Lazăr,
Cristiana Oprea,
Adriana Moţoc,
Daniel Codreanu,
A.G. Kosa,
Emanoil Ceauşu
Publication year - 2016
Publication title -
romanian journal of infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 2069-6051
pISSN - 1454-3389
DOI - 10.37897/rjid.2016.4.1
Subject(s) - ribavirin , cirrhosis , medicine , adverse effect , hepatitis c virus , interferon , gastroenterology , population , hepatitis c , virology , virus , environmental health
The article describes the adverse effects and efficiency of hepatitis C virus liver cirrhosis treatments available through the National Health Insurance Services, on a population of patients hospitalized at Victor Babes Infectious and Tropical Diseases Hospital, from 2012 to 2016. The population of patients was split into two distinct groups, for which we’ve recorded and comparatively analyzed demographic, clinical and paraclinical characteristics in a database. An evident success was recorded, from the point of view of hitting a clinical SVR index, in the DAA therapy group A, 87% percent compared to 2% in group B for the traditional standard therapy of PegInterferon + Ribavirin. Likewise, the number of adverse effects was lower in Group B versus Group A. Some side effects remained specific to the current cirrhosis treatment, which should be closely monitored.